Hematologic Malignancies

Cancer in the bloodstream can be just as aggressive as cancers that form solid masses. Fortunately, the long-term strategies offered by City of Hope’s Hematologic Malignancies (HM) Program have dramatically improved the lives of patients with leukemia, lymphoma, Hodgkin’s disease and multiple myeloma — the various cancers associated with blood and plasma.
 
Intensive studies within the leading-edge HM program use clinical research to target and treat the two major types of blood cells (myeloid and lymphoid) that generate malignant blood cancer.
 
Led by internationally renowned physicians Stephen J. Forman, M.D., and Wing-Chung (John) Chan, M.D., HM pursues three powerful objectives:
  • To identify key biological pathways and targeting strategies for hematologic malignancies.
  • To develop novel therapeutic approaches for early-phase clinical testing.
  • To advance translational research in hematopoietic cell transplantation (HCT) and adoptive cellular immunotherapy (ACIT).

The HM Program improves public health both through its refinement of currently available treatment options for hematological malignancies and its advancement of novel therapies to the clinic. The team explores multiple avenues of treatment – chemotherapy, immunotherapy, gene therapy, targeted therapy, chimeric antigen receptor (CAR) T cell therapy and hematopoietic cell transplantation – to improve patient cure rates and treatment tolerability.

By bringing together clinical and basic scientists in dynamic ways, City of Hope’s clinical transplant activities are enriched by studies into individual diseases (leukemia, myelomas, lymphomas and Hodgkin’s disease). The result enables a comprehensive, coordinated approach to treating cancer in all its forms — in the bloodstream and elsewhere.